member login


Find our blog: News from the Vaccine World



Marie Skłodowska-Curie actions

European Research fellowship programma



VaccineNation, a website run by Terrapinn a business media company

VaccinesToday, sponsored by Vaccine Europa, the professional association of the pharmaceutical industry in Europe

VaccineOrb, a website run by Elsevier

The Edward Jenner Vaccine Society, an academic vaccine society

The International Society for Vaccines, an organization founded and run by vaccinologists

The Vaccine Confidence Project, an initiative to monitor public confidence in immunisation programmes


IPROVE: innovation partnership for a roadmap on vaccines in europe

December 2013 - December 2015


The “Innovation Partnership for a Roadmap on Vaccines in Europe” (IPROVE) - financed under the EU 7th Framework Programme (FP7) - aims to establish a clear vision of the priority innovations and technologies to boost research in the field of vaccine and vaccinology necessary to address infectious and non-infectious threats of importance to public health in Europe and beyond. Issues to be addressed will include inter-alia R&D needs to develop vaccines for the ageing population, emerging threats from hospital infections, high incidence of chronic diseases, low levels of prevention awareness and readiness, as well as the suboptimal use of existing cost-effective vaccines across different age groups.






TBVAC2020 aims to innovate and diversify the current TB vaccine and biomarker pipeline while at the same time applying portfolio management using gating and priority setting criteria to select as early as possible the most promising TB vaccine candidates, and accelerate their development. TBVAC2020 proposes to achieve this by combining creative “bottom-up” approaches for vaccine discovery, new preclinical models addressing clinical challenges and identification and characterisation of correlates of protection with a directive “top-down” portfolio management approach aiming to select the most promising TB vaccine candidates by their comparative evaluation using objective gating and priority setting criteria and by supporting direct, head-to head or comparative preclinical and early clinical evaluation. This approach will both innovate and diversify the existing TB vaccine and biomarker pipeline as well as accelerate development of most promising TB vaccine candidates through early development stages.



Advanced Immunization Technologies (ADITEC)

October 2011-September 2016


Project description: Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible.

The scope of this project is to produce knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach in which diverse but complementary scientific disciplines and technologies converge. Therefore some of the most competitive European research groups from public institutions and biotechs have agreed to join forces in ADITEC, together with top US groups on systems biology and adjuvants to support this enterprise.

A systems biology approach will be used to study licensed and experimental vaccines in patient characterization studies and in clinical trials, to investigate the effect of adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous prime–boost schedules, as well as the impact of host factors such as age, gender, genetics and pathologies. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic.

To address these issues in a coordinated manner, ADITEC is organised on a matrix structure in which research themes and experimental approaches feed into each other. Training curricula will be created to impact on the formation of the next generation of EU researchers in the field. Several ADITEC scientists and institutions are part of the “Sclavo Vaccines Association” (SVA), which is dedicated to vaccines and vaccine research. SVA, acting as the coordinating institution, guarantees the long-term commitment and sustainability of this initiative, beyond the duration of ADITEC itself.



Biomarkers for enhanced vaccines immunosafety (BioVacSafe)

March 2012-February 2017


Project description: BioVacSafe is a 5 year project funded by the Innovative Medicine Initiative (IMI). The goal of BioVacSafe is to develop cutting edge tools to speed up and improve the testing and monitoring of vaccine safety, both before and after release to the market. BioVacSafe aims at establishing tools, methods and guidelines for the evaluation of vaccine reactogenicity and enhancing immunosafety of novel vaccines. By bringing together for the first time three of Europe's leading vaccine development and manufacture companies as well as top experts from academic institutes and small and medium-sized enterprises (SMEs), the project will ultimately accelerate the development and introduction of a new generation of safer, more effective vaccines. By sharing their expertise, the BioVacSafe partners have a unique opportunity to make progress in this important area.



Adenoviruses as novel clinical treatments (ADVance)

April 2012-March 2016


Project description: ADVance is designed to integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to train young scientists in adenovirus (AdV) research. Our full partners and industrial partners represent internationally leading academic centres of excellence in key facets of research into the basic biology of AdV and their application as vectors for clinical protocols in cancer, cardiovascular disease and vaccination that is unique as a training opportunity. Our academic and private sector full partners represent a key areas critical to improved understanding of adenovirus biology and development of key underpinning technology for translational AdV research at the highest level and will create a training opportunity of the highest calibre. The training components are further complemented by our associated partners EASCO that will integrate into ADVance a broad interdisciplinary training and dissemination program. This will ensure the very best training in scientific and key non-scientific skills for each recruited ESRs and ERs. We have also recruited Glen Nemerow as a visiting researcher for his depth of understanding and experience in AdV research over many years. ESR will benefit extensively from the complementarity between the host institutes and strength in depth in training for future careers as well as elevated long term research links for host institutes and companies in the longer term. The network research training is based on a group of well defined and highly innovative research projects applying state-of-the-art methodologies. ADVance will allow lasting collaborations between partners, with and extensive plan of inter-partners secondments of ESR/ERs, which will and create a critical mass of focused adenovirus biologists and translationnal scientists and allow our recruited young researchers to start an excellent career in this field...



Host Microbe Interactions in Health and Disease: Interface with the Immune System (HOMIN)

April 2013-March 2017


Project description: HOMIN is designed as an advanced education and research program meant to train junior investigators possessing medical and/or scientific educational backgrounds to become future leading scientists in academic institutions, private companies, or administration.
The HOMIN objectives are:
1. To provide multidisciplinary and intersectorial scientific education through the study of host-microbe interactions, particularly focusing on immune responses and vaccine development. To this end, HOMIN will provide: Cutting-edge scientific projects in subjects in which the HOMIN partners are international leaders. A collaborative scientific environment, allowing the young researchers to appreciate research in the academic and the private sector, and their connections at the European level. Scientific communication and networking opportunities at the European and International levels.
2. To provide an exceptional nurturing environment through an outstanding academic-private sector laboratory network composed of 7 academic partners and 5 companies of different sizes and activities, including 3 SME. The private sector is represented as full partner and associated partner, contributing significantly to training at all the possible levels, from research supervision, to teaching and training organisation. In this environment, young researchers will be aware of biomedical research and its potential industrial applications for human disease prevention and treatment.
3. To endow with an array of complementary training on scientific, as well as transferable skills, aimed at developing the young researchers creativity, curiosity, adaptability, auto-evaluation capacity, feeling for innovation and discovery application, capacities for team work, for preparing a proposal and for communicating on science to different audiences. HOMINs goal is to promote the development of the conscious identity of young scientists preparing them for a broad professional spectrum and to strengthen the ERA.



Vaccine Design and Immune Responses (VADER)

October 2012-September 2016


Project description: The successful development of new vaccines depends on the interaction of industrial expertise for vaccine design and engineering with academic understanding of the mechanisms of protection afforded by the immune responses they elicit. Close interaction between both sectors expedites vaccine development and, in the context of global health, this can translate to the saving of thousands of lives. The VADER (Vaccine Design and Immune Responses) EID programme, established between the Novartis Vaccines Institute for Global Health (NVGH) in Italy and University of Birmingham (UoB) in the UK, will train four talented clinical and non-clinical fellows at the interface between academia and industry. NVGH is a company with a mission to develop affordable and effective vaccines against infectious diseases of impoverished communities in the developing world. Its first vaccine, against Salmonella Typhi, is in clinical trails in South-East Asia, with vaccines against Salmonella Paratyphi, nontyphoidal Salmonella, meningococcus and Shigella in preclinical development. UoB is an international leader in investigating immune responses to bacteria, particularly Salmonellae, and in relating immunity to microbial antigens. The two institutions have forged strong links over the last year which form the framework of the VADER programme. The fellows will work on four related projects embedded within existing vaccine programmes at NVGH where they will work as part of a team of scientists. With vaccines in clinical trials, trainees will be able to explore immune responses in human vaccinees as well as animals. In their projects, they will be trained in vaccine design and immunology and learn how differences in vaccine engineering affect immune responses. By working on both industrial and academic sides of vaccine development they receive research training in translational and transferable skills and learn how both sectors can synergise in vaccine development.



TRANSVAC: New vaccines faster

October 2009-September 2013 (completed)


Project description: TRANSVAC is a collaborative infrastructure project funded under the 7th Framework Programme of the European Commission. The project is the joint effort of leading European groups in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC was designed in order to enhance EUropean research and training and foster the seamless implementation of a permanent research infrastructure for early vaccine development in Europe. In order to reach its ambitious goal, TRANSVAC carries out activities at various levels. On their website you can find out about how to benefit from TRANSVAC's portfolio of activities, learn how to apply for access to the high-quality infrastructure free services and paid services, how to participate in the free Workshops on Animal Models or in the free Modular Course on Concepts on Vaccine Development. Finally, TRANSVAC looks to the future and is exploring the implementation of a road map towards a sustainable European vaccine development platform beyond TRANSVAC. This is dome by the European Vaccine Development Stakeholder Working Groups.  



European Initiative for basic research in Microbiology and Infectious Diseases (EIMID)

December 2008-November 2012 (completed)


Project description: The EIMID-IAPP training programme is part of the European Initiative for Basic Research in Microbiology and Infectious Diseases (EIMID), created in 2003 by scientists of five European centres of excellence (the Max Planck Institute for Infection Biology in Berlin, the CMMI at Imperial College in London, the Institut Pasteur in Paris, the Karolinska Institutet in Stockholm; and the vaccine company Novartis in Siena). By building a strong coalition among these institutes, EIMID aims at setting the basis for a future no-wall European Institute of Microbiology and Infectious Diseases, as part of the European Research Area (ERA). EIMID-IAPP aims at implementing the Industry-Academia cooperation through an integrated programme of exchange of young researchers between the industrial partner and the four academic institutions. The goal of the collaborative project is the development of Novel Therapeutic Approaches against Infectious Diseases, with particular emphasis to drug-based and vaccine-based therapies for bacterial infections affecting mucosal surfaces. Four researchers will be seconded from the industrial partner to the four academic institutions and vice-versa. Each secondment will be for two years (with a six month intermission for intermediate knowledge transfer to the mother institution), and the seconded staff between two institutions will investigate complementary aspects of the same project sub-area. Each institution will also recruit an experienced researcher for two years, to acquire new expertise and technologies necessary to the project development. A series of informal discussions, and annual general meetings, will allow constant exchange of information and efficient project steering. This activity of Industry-Academia exchange fulfils the EIMID goals of 1) harmonising European research programmes, so as to achieve a critical mass on relevant topics. 2) fostering exchange of scientists, particularly at the doctoral and post-doctoral levels.

Funded by the EU under the FP7 Marie Curie Action - Grant number: 316655